Designed for the specific identification and differentiation of the new coronavirus in clinical samples, the VIASURE SARS-CoV-2 Real-Time PCR Detection Kit is available now from Pro-Lab Diagnostics. Currently, there are two versions of the kit available: VS-NCO1 monoplex, which amplifies a fragment of the S gene of the virus; and VS-NCO2 multiplex, which amplifies and identifies fragments of the ORF1ab and N genes.
The Native Antigen Company, a leading supplier of reagents for research into vaccines and diagnostics for emerging and endemic infectious diseases, has announced the commercial introduction of its novel coronavirus antigens, derived from the COVID-19 strain.
A ground-breaking test for the potentially fatal COVID-19 strain of coronavirus is available at global health diagnostics company Randox Laboratories. The test, developed on Randox’s patented Biochip Technology, is as an enhanced multiplex array which includes tests for COVID-19 and nine other respiratory viruses that can display the same symptoms. The new enhanced biochip therefore allows clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections.
A novel coronavirus diagnostic test developed by Public Health England (PHE) is being rolled out to laboratories across the UK. The increase in diagnostic capacity from one laboratory in London to 12 elsewhere over the coming weeks will accelerate the country’s testing capabilities.
InterSystems is releasing global functionality for its TrakCare unified healthcare information system to screen and support patients infected with the novel coronavirus 2019-nCoV. The functionality is available to users of the latest editions of TrakCare now, and customers in China and numerous other countries, including the UK and United Arab Emirates, have already begun using it.
A ground-breaking test for the potentially fatal 2019-nCoV strain of coronavirus is in the final stages of development at global health diagnostics company Randox Laboratories. The soon-to-be-launched test, developed on Randox’s patented Biochip Technology, will be available for immediate 2019-nCoV testing, but an additional enhanced multiplex array will also include tests for other respiratory viruses which can display the same symptoms. The new enhanced Biochip will therefore allow clinicians quickly and efficiently to differentiate between potentially lethal and non-lethal infections.
Public Health England has issued guidelines for hospital laboratories in case coronavirus infection arrives in the UK. Public fears are growing, but biomedical scientists who specialise in viruses and viral diseases are prepared should cases reach their hospitals.
Coronaviruses are RNA viruses that infect many animal species. In humans they usually cause mild respiratory disease similar to the common cold. However, two recent outbreaks of acute respiratory illness have occurred; severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These coronaviruses both caused severe illness with high mortality rates.